Company: BLRX
Filing Date: 2025-03-31
Form Type: 20-F
Source: 0001178913-25-001123
Chunk: 59

Company: BioLineRx Ltd.
Filing Date: 2025-03-31
Form: 20-F
Item: Item 3
Chunk 59
---
.

We are continuing to advance the development of motixafortide for
patients with pancreatic cancer and other solid tumors.

33

In addition, as part of our growth strategy, we are actively pursuing
in-licensing opportunities to expand and diversify our product pipeline. We are specifically targeting innovative therapeutic candidates
that complement our existing portfolio and align with our core expertise in oncology and rare disease. Our business development team is
evaluating potential assets across various stages of development, from preclinical to late-stage clinical programs. We maintain a disciplined
approach to asset acquisition, focusing on opportunities that offer significant market potential, address unmet medical needs, and can
leverage our established development and commercialization capabilities. Through these strategic in-licensing efforts, we aim to enhance
shareholder value while advancing our mission of bringing novel therapies to patients in need. See also “ Item 4. B. Information on
the Company - In-Licensing Agreements.”

Our Product Pipeline

The table below summarizes key information about our products and
our clinical programs:

Motixafortide

Motixafortide is a novel, short peptide that functions as a high-affinity
antagonist of CXCR4, used in the treatment of stem cell mobilization and solid tumors. CXCR4 is expressed by normal hematopoietic cells
and overexpressed in various human cancers where its expression correlates with disease severity. CXCR4 is a chemokine receptor that mediates
the homing and retention of hematopoietic stem cells, or HSCs, in the bone marrow, and also mediates tumor progression, angiogenesis (growth
of new blood vessels in the tumor), metastasis (spread of tumor to other organs) and survival. Before “motixafortide” was
approved by the World Health Organization, or WHO, in 2019 as an International Nonproprietary Name, this therapeutic candidate was known
as “ BL-8040”. In October 2021, we received WHO approval of the United States Adopted Name, or USAN, “motixafortide”.
The FDA-approved trade or brand name of motixafortide is APHEXDA.

Inhibition of CXCR4 by motixafortide leads to the mobilization
of HSCs from the bone marrow to the peripheral blood, enabling their collection for subsequent autologous or allogeneic transplantation
in cancer patients. Clinical data has demonstrated the ability of motixafortide to mobilize higher